These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25987796)

  • 1. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.
    Israeli E; Zigmond E; Lalazar G; Klein A; Hemed N; Goldin E; Ilan Y
    World J Gastroenterol; 2015 May; 21(18):5685-94. PubMed ID: 25987796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
    Margalit M; Israeli E; Shibolet O; Zigmond E; Klein A; Hemed N; Donegan JJ; Rabbani E; Goldin E; Ilan Y
    Am J Gastroenterol; 2006 Mar; 101(3):561-8. PubMed ID: 16542292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.
    Israeli E; Goldin E; Shibolet O; Klein A; Hemed N; Engelhardt D; Rabbani E; Ilan Y
    World J Gastroenterol; 2005 May; 11(20):3105-11. PubMed ID: 15918198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
    Duijvestein M; Vos AC; Roelofs H; Wildenberg ME; Wendrich BB; Verspaget HW; Kooy-Winkelaar EM; Koning F; Zwaginga JJ; Fidder HH; Verhaar AP; Fibbe WE; van den Brink GR; Hommes DW
    Gut; 2010 Dec; 59(12):1662-9. PubMed ID: 20921206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
    Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
    Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
    N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease.
    Sands BE; Katz S; Wolf DC; Feagan BG; Wang T; Gustofson LM; Wong C; Vandervoort MK; Hanauer S
    Gut; 2013 Sep; 62(9):1288-94. PubMed ID: 22760005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study.
    Jauregui-Amezaga A; Cabezón R; Ramírez-Morros A; España C; Rimola J; Bru C; Pinó-Donnay S; Gallego M; Masamunt MC; Ordás I; Lozano M; Cid J; Panés J; Benítez-Ribas D; Ricart E
    J Crohns Colitis; 2015 Dec; 9(12):1071-8. PubMed ID: 26303633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trichuris suis therapy in Crohn's disease.
    Summers RW; Elliott DE; Urban JF; Thompson R; Weinstock JV
    Gut; 2005 Jan; 54(1):87-90. PubMed ID: 15591509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
    van der Woude CJ; Stokkers P; van Bodegraven AA; Van Assche G; Hebzda Z; Paradowski L; D'Haens G; Ghosh S; Feagan B; Rutgeerts P; Dijkstra G; de Jong DJ; Oldenburg B; Farhan M; Richard T; Dean Y; Hommes DW;
    Inflamm Bowel Dis; 2010 Oct; 16(10):1708-16. PubMed ID: 20848453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.